In fact, at least in this population, diabetes, obesity and the metabolic syndrome seem to override the influence of PCSK9 on LDL metabolism, as demonstrated by the loss of the correlation between PCSK9 and LDL cholesterol in patients with altered metabolic phenotype (Fig. 3). This evidence concerns the gene PCSK9 and obesity due to melanocortin 4 receptor deficiency.